NEXGEL Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 1/6

Wichtige Informationen

14.4%

Verhältnis von Schulden zu Eigenkapital

US$750.00k

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$2.42m
Eigenkapital	US$5.21m
Gesamtverbindlichkeiten	US$5.18m
Gesamtvermögen	US$10.39m

Jüngste Berichte zur Finanzlage

Recent updates

NexGel: Old Wine In A New Bottle

Jan 30

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: NXGL über mehr Barmittel verfügt als seine Gesamtverschuldung.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: NXGL hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: NXGL hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 19.9% pro Jahr abnimmt

NEXGEL Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

NEXGEL, Inc. announced delayed annual 10-K filing

Recent updates

NEXGEL, Inc. to Report Q1, 2024 Results on May 13, 2024

NEXGEL, Inc., Annual General Meeting, Jun 17, 2024

NEXGEL, Inc. announced delayed annual 10-K filing

Forecast breakeven date pushed back to 2026

NEXGEL, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

NEXGEL, Inc. has filed a Follow-on Equity Offering.

NEXGEL, Inc. has filed a Follow-on Equity Offering.

NEXGEL, Inc. has filed a Follow-on Equity Offering.

NEXGEL, Inc. Announces Intention of Miranda J. Toledano to Resign as a Member of the Board of Directors, Effective as of March 31, 2024

NEXGEL, Inc. Announces Resignation of David Stefansky as Member of the Board of Directors

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

NEXGEL, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Price target increased by 20% to US$6.00

New major risk - Market cap size

New major risk - Market cap size

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

NEXGEL, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Consensus revenue estimates increase by 62%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

NEXGEL, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

NEXGEL, Inc. Announces Directorate and Committee Changes

Nexgel Appoints Scott Henry, to Board of Directors and Audit Committee

Forecast to breakeven in 2025

NEXGEL, Inc. Launches Turfguard to Treat Painful Turf Burns and Protect Sports-Related Wounds

NEXGEL, Inc. (NasdaqCM:NXGL) announces an Equity Buyback for $0.5 million worth of its shares.

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

NEXGEL, Inc. to Report Q3, 2022 Results on Nov 08, 2022

NEXGEL, Inc. Reports Positive Results from Proof-Of-Concept Study for Its Diclofenac Hydrogel Pain Treatment

Nexgel, Inc. Develops New Hydrogel Patch to Treat Amblyopia

NEXGEL, Inc. Announces SAGE Journals Publishes New Data Revealing SilverSeal Hydrogel Dressing Improves Postsurgical Scarring

NEXGEL, Inc. Announces Scientific Advisory Board Appointments

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NEXGEL, Inc. to Report Q2, 2022 Results on Aug 10, 2022

NEXGEL Launches Medagel Hydroliner Pro Pads for Eyelash Protection During Cosmetic Extensions Service

NEXGEL, Inc., Annual General Meeting, Aug 30, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

NEXGEL, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

NexGel: Old Wine In A New Bottle

NEXGEL, Inc. Announces the Launch of MEDAGEL ClearComfort Hydrogel Patch

NEXGEL, Inc. has completed an IPO in the amount of $14.235131 million.

High number of new and inexperienced directors

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen